News
-
Professor Nishikawa’s Paper Published in Nature
Research findings suggesting the potential to enhance the efficacy of cancer immunotherapy, not only with immune checkpoint inhibitors but also with treatments like immune cell therapy.
More
-
Artwork at Cafe zone
Designed by Blake Thompson
More
-
Independent PI Opportunity: New Call Announced
CCII is now recruiting Junior Group Leaders
More
-
New pictures of Bristol Myers Squibb Building
New photos of the BMS Building uploaded.
More
-
Bristol Myers Squibb Japan visited CCII
BMS–CCII Partnership Maintained and Strengthened.
More
Events
-
The 38th CCII Seminar “Leveraging metabolomics and biological networks for functional insights into microbiome” (Jianguo (Jeff) Xia)
More
-
The 37th CCII Seminar “The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma” (Ian Watson)
More
-
The 36th CCII Seminar on “Replaying germinal center evolution on a quantified affinity landscape” (Gabriel Victora)
More
-
Workshops : Experimental Design and Adaptation in Immunological Research
More
-
Peer Review Workshop (Thiago Carvalho)
More
FEATURED NEWS FROM CCII
-
NewsHighlights of CCII Opening Events
On 12th November 2024, we celebrated the Opening Ceremony for the newly constructed Bristol Myers Squibb Building, located on the Kyoto University campus, and serving as the hub for CCII's activities. Our 1st Symposium on Cancer Immunotherapy and Immunobiology followed from 13th to 15th November. Have a look at the newly published highlights!
-
NewsCCII Introduction Video Now Live!
Founded in April 2020 within Kyoto University’s Graduate School of Medicine, CCII is at the forefront of groundbreaking research in cancer immunotherapy. In this video, Kyoto University President Nagahiro Minato, CCII Director Tasuku Honjo, world-renowned architect Tadao Ando, and leading CCII researchers share insights into our center’s mission and activities.
-
ResearchPD-1 & the Immune Therapy Revolution: A 30-Year Journey
With the advent of PD-1 checkpoint inhibitors, specially designed antibodies that prevent the PD-1 protein from blocking immune cells to fight cancer, the idea of enrolling the immune system in the fight against cancer has finally become a clinical reality. However, there are still cancer patients that do not respond to PD-1 antibodies, and further research is needed to improve existing approaches.
-
ResearchRethinking the Immune Response as Metabolic Process
Immune responses are energetically expensive. Not surprisingly, secreted metabolites are increasingly emerging as important factors in immune cell maturation and activation, as this new review published in Trends in Immunology by Sidonia Fagarasan et al. demonstrates.
-
ResearchSpermidine to the Rescue?
Spermidine, a polyamine compound found in ribosomes and living tissues and originally isolated from semen, is an increasingly popular anti-aging supplement. Muna Al-Habsi and her colleagues demonstrate in a new paper published in Science that spermidine can enhance cancer immunotherapy blocking the PD-1 pathway by reversing aging effects in killer T-cells.
-
RecruitWe are permanently recruiting!
We are permanently recruiting highly motivated students, postdoctoral fellows, scientists, and technical staff. Please contact us!